Welcome to our dedicated page for Esperion Therapeutics news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therapeutics stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a leading pharmaceutical company specializing in the development and commercialization of innovative, first-in-class, oral therapies aimed at lowering low-density lipoprotein cholesterol (LDL-C). The company's flagship product, ETC-1002, is a potent inhibitor of ATP citrate lyase, an enzyme integral to the cholesterol biosynthesis pathway. This pathway also includes HMG-CoA reductase, the enzyme targeted by statins.
Esperion has made significant progress with ETC-1002, completing Phase 1 and Phase 2 clinical trials, and is set to initiate Phase 3 trials. The company's product lineup includes NEXLETOL and NEXLIZET, both of which are oral, once-daily, non-statin medications designed to tackle elevated LDL-C levels. These drugs have recently received expanded FDA approval for cardiovascular risk reduction and are indicated for both primary and secondary prevention patients.
In recent news, Esperion announced that both NEXLETOL and NEXLIZET have received broad new label expansions. These labels now cover cardiovascular risk reduction and expanded LDL-C lowering, either alone or in combination with statins. This approval allows over 70 million patients to access these life-saving drugs, positioning them as the non-statin drugs of choice for cardiovascular risk management.
Esperion is also ramping up its marketing and promotional efforts, enhancing patient support programs, and working with payers to improve patient access. The company is committed to breaking barriers in cardiovascular care and continues to focus on underserved populations, including women and Hispanic/Latinx patients, as demonstrated by their recent CLEAR Outcomes trial.
The company's forward-looking strategy includes ongoing clinical development, financial management, and expansion into new markets. Esperion's dedication to transforming cardiovascular care is evident in its robust pipeline and strategic initiatives aimed at addressing critical unmet medical needs.
Esperion (NASDAQ: ESPR) announced that CEO Sheldon Koenig will participate in a fireside chat at the Bank of America Securities 2023 Health Care Conference on May 11, 2023, at 11:40 AM PDT. Interested parties can register for the live webcast through a provided link.
A live audio broadcast will be available on the investor section of Esperion's website, with a replay set to be accessible about two hours post-event and archived for roughly 90 days.
Esperion is focused on developing medicines for patients with cardiovascular diseases, addressing the urgent need for effective treatments to lower LDL-cholesterol levels.
Esperion (NASDAQ: ESPR) announced it will report its first quarter 2023 financial results on May 9, 2023, before the U.S. markets open. Following this, management will host a webcast at 8:00 a.m. ET to discuss the financial results and business progress. The event will be accessible through the investor section of the Esperion website, with a replay available approximately two hours later. Esperion is focused on developing innovative medicines for patients with cardiovascular and cardiometabolic diseases, particularly aiming to manage high cholesterol levels effectively.
Esperion (NASDAQ: ESPR) has announced a performance-based agreement with Currax Pharmaceuticals, allowing Currax’s 72 sales representatives to co-promote its cholesterol-lowering products, NEXLETOL® and NEXLIZET®. This partnership significantly increases the sales force for these products, reflecting Esperion’s commitment to sustained growth. The agreement aims to leverage the positive momentum from the CLEAR Outcomes trial, involving nearly 14,000 patients, which evaluated the cardiovascular benefits of NEXLETOL. Both medications are indicated for patients requiring additional LDL-C reduction. Important safety information includes warnings about hyperuricemia and tendon rupture. The collaboration lasts through the end of 2023, focusing on elevating awareness and utilization of these treatments.
Esperion (NASDAQ: ESPR) has announced that Sheldon Koenig, the company's president and CEO, will participate in a fireside chat at Needham's 22nd Annual Virtual Healthcare Conference on April 17, 2023, at 8:45 AM ET. This event will provide insights into the company's innovative approaches in treating cardiovascular and cardiometabolic diseases. Interested parties can register for the live webcast through the provided link. A recorded version will be available for 90 days post-event.
FAQ
What is the current stock price of Esperion Therapeutics (ESPR)?
What is the market cap of Esperion Therapeutics (ESPR)?
What is Esperion Therapeutics, Inc.?
What products does Esperion offer?
What recent achievements has Esperion made?
What is ETC-1002?
What is the significance of the CLEAR Outcomes trial?
Who can benefit from Esperion's medications?
What partnerships does Esperion have?
What are the common side effects of NEXLETOL and NEXLIZET?
How does Esperion support its patients?
What are Esperion's future plans?
